Clinical Trial Update: The Effect of Glucagon-Like Peptide-1 (GLP-1) on Pulmonary Vascular Resistance (PVR) in Patients With Heart Failure [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the effect of glucagon-like peptide-1 on pulmonary vascular resistance in patients with heart failure has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• GLP-1 (glucagon-like peptide-1)

Snippet

Sponsor: Papworth Hospital NHS Foundation Trust | Conditions: Heart Failure | Phase 1 | Status: COMPLETED